Abstract:According to the 2021 Malaria report, 241 million clinical episodes with 627000 deaths penalty was estimated across the worldwide. However, mutation in the propeller domain of Plasmodium falciparum kelch 13 protein resulted in longer parasite clearance time following an artemisinin-based treatment and had a greater survival rate of ring-stage parasites even after a brief exposure to a high dose of artesunate. Clinical manifestations become more complex and worse with the emerging trend of drug resistance against artemisinin derivatives and the poor effectiveness of malaria vaccination drive. Steroidal lactone (withanolide) moiety (C-28) isolated from methanolic leaf extract Withania somnifera show a greater affinity towards Pfkelch 13 protein in comparison to the artemisinin derivatives (artesunate, artemether). The isolated compound was characterized to be withaferin A with a percentage yield of 29.01% w/w in chloroform fraction, 1.75% w/w in methanolic extract, and 0.29% w/w in raw leaf powder. Structure-based analysis shows that withaferin A (docking score −8.253, −9.802) has a higher affinity for two distinct binding pockets I and II of the Plasmodium falciparum kelch 13 protein than artesunate (docking score −4.470, −3.656). Further, Gibbs binding free energy signifies thermodynamic stability of the docked complex of withaferin A (-43.25, −43.76 Kcal/mol) in comparison to artesunate docked complex (-8.49, −5.75 Kcal/mol). The pharmacokinetic profile of withaferin A shows more drug-likeness characteristics without violating Jorgensen's rule of three, and Lipinski's rule of five. Hence above experimental findings suggest withaferin A could be a suitable therapeutic adjunct for preclinical evaluation of antimalarial potentiality in artemisinin-resistant malaria. Malaria is a life-threatening parasitic disease caused by Plasmodium species. The emerging trend of artemisinin resistance and severe side effects (CNS and cardiotoxicity) are the potential challenges faced by antimalarial therapeutics. Artemisinin-mimic potentiality (ROS-mediated antiparasitic activity) of withaferin A shows a strong affinity towards artemisinin resistance Plasmodium falciparum kelch 13 protein. The pharmacokinetic profiling of the withaferin A signifies its drug-likeness characteristics without violating Jorgensen's rule of three, and Lipinski's rule of five. Based on molecular docking and pharmacokinetic profiling, withaferin A could be a suitable therapeutic adjunct for preclinical investigation of antimalarial potentiality in artemisinin-resistant malaria. Graphical Communicated by Ramaswamy H. Sarma

Development, characterization, and evaluation of withaferin-A and artesunate-loaded pH-responsive acetal-dextran polymeric nanoparticles for the management of malaria

Design and Antimalarial Evaluation of Polydopamine-Modified Methyl Artelinate Nanoparticles

Preparation, optimization, and evaluation of ligand-tethered atovaquone-proguanil-loaded nanoparticles for malaria treatment

Artesunate-heparin Conjugate Based Nanocapsules with Improved Pharmacokinetics to Combat Malaria

Pharmacokinetic study of intravenously administered artemisinin-loaded surface-decorated amphiphilic γ-cyclodextrin nanoparticles

Improved Anti-Malarial Parasite Efficacy with Heparin-Artemisinin Nanoemulsions

Isolation and structure elucidation of a steroidal moiety from Withania somnifera and in silico evaluation of antimalarial efficacy against artemisinin resistance Plasmodium falciparum kelch 13 protein

Liposomes of Dimeric Artesunate Phospholipid: A Combination of Dimerization and Self-Assembly to Combat Malaria.

Enhanced Antimalarial Efficacy Obtained by Targeted Delivery of Artemisinin in Heparin-Coated Magnetic Hollow Mesoporous Nanoparticles

Co-delivery of Artemether and Piperine Via Core-Shell Microparticles for Enhanced Sustained Release

Dimeric Artesunate Glycerophosphocholine Conjugate Nano-Assemblies As Slow-Release Antimalarials to Overcome Kelch 13 Mutant Artemisinin Resistance

Antimalarial activity assay of artesunate-3-chloro-4(4-chlorophenoxy) aniline in vitro and in mice models

Heparin-decorated nanostructured lipid carriers of artemether-protoporphyrin IX-transferrin combination for therapy of malaria

Preparation and in vivo evaluation of anti-plasmodial properties of artemisinin-loaded PCL–PEG–PCL nanoparticles

Characteristics of Artemether-Loaded Poly(lactic-co-glycolic) Acid Microparticles Fabricated by Coaxial Electrospray: Validation of Enhanced Encapsulation Efficiency and Bioavailability.

Dual-pharmacophore artezomibs hijack the Plasmodium ubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance

Plant-based nanoparticles targeting malaria management

Enhanced Antimalarial and Antisequestration Activity of Methoxybenzenesulfonate-Modified Biopolymers and Nanoparticles for Tackling Severe Malaria

Dual-pharmacophore artezomibs hijack the <i>Plasmodium</i> eubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance

Preparation and In-Vitro Characterization of Solid Lipid Nanoparticles Containing Artemisinin and Curcumin

Unveiling Potential Repurposed Drug Candidates for Plasmodium falciparum through In Silico Evaluation: A Synergy of Structure-based Approaches, Structure Prediction, and Molecular Dynamics Simulations